Ligand Pharmaceuticals | LGND - Gross Profit On Sales


Ligand Pharmaceuticals reported $100.41M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Agenus USD 33.74M 468K Mar/2026
Amgen USD 5.87B 1.02B Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 73.74M 190.3M Mar/2026
Baxter International USD 1.14B 251M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Enviri Corporation USD 83.01M 37.46M Dec/2025
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 356.19M 99.73M Jun/2026
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Pacira USD 133.91M 7.27M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Veracyte USD 108.55M 7.39M Jun/2026